Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
Phase 2 Terminated
5 enrolled
ISAKIDS
Phase 2 Terminated
67 enrolled 25 charts
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase 1/2 Terminated
4 enrolled 8 charts
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
Phase 2 Terminated
11 enrolled 13 charts
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Phase 1/2 Terminated
17 enrolled 15 charts
Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
Phase 2 Terminated
4 enrolled 11 charts
EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)
Phase 1 Terminated
6 enrolled 11 charts
Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda
Phase 1 Terminated
18 enrolled
Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia
Phase 2 Terminated
59 enrolled 8 charts
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
Phase 2 Terminated
26 enrolled 11 charts
Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma
Phase 2 Terminated
6 enrolled 7 charts
CATHY
Phase 3 Terminated
11 enrolled 10 charts
Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase 2 Terminated
11 enrolled 6 charts
BMT CTN 0202
Phase 2/3 Terminated
30 enrolled 5 charts
Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 2 Terminated
6 enrolled 10 charts
Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma
Phase 2 Terminated
31 enrolled
Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL
Phase 1 Terminated
3 enrolled
Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas
Phase 4 Terminated
100 enrolled
The Use of Chemotherapy Plus Radiotherapy Plus Azidothymidine in Patients With AIDS-Related Lymph Node Cancer
Phase NA Terminated
45 enrolled
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Phase 2 Terminated
2 enrolled 7 charts
Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation
Phase 3 Terminated
105 enrolled
ABT-751 With Chemotherapy for Relapsed Pediatric ALL
Phase 1/2 Terminated
9 enrolled 12 charts
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
Phase 1/2 Terminated
23 enrolled 13 charts
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Phase 1/2 Terminated
23 enrolled 12 charts
Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 1 Terminated
12 enrolled
Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)
Phase 2 Terminated
21 enrolled 13 charts
Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL
Phase 2 Terminated
10 enrolled
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
Phase 2 Terminated
6 enrolled 14 charts
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
Phase 2 Terminated
2 enrolled 11 charts
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Phase 2 Terminated
3 enrolled 6 charts
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis
Phase 2 Terminated
60 enrolled
Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)
Phase 1 Terminated
1 enrolled 7 charts
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase 2 Terminated
1 enrolled 4 charts
Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma
Phase 1/2 Terminated
5 enrolled 9 charts
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
Phase 2 Terminated
12 enrolled 10 charts
Cyclosporine Plus Methotrexate or Alemtuzumab
Phase 2 Terminated
72 enrolled
Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
Phase 2 Terminated
15 enrolled 8 charts
Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
Phase 2 Terminated
2 enrolled 6 charts
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
Phase 2 Terminated
200 enrolled 11 charts
Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases
Phase 2 Terminated
1 enrolled 5 charts
CICLODECH
Phase 3 Terminated
3 enrolled
Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma
Phase 2 Terminated
22 enrolled 8 charts
Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia
Phase 2 Terminated
22 enrolled 11 charts
Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 2 Terminated
12 enrolled 6 charts
A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.
Phase 2 Terminated
5 enrolled 3 charts
Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
Phase 2 Terminated
8 enrolled 11 charts
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
Phase 2 Terminated
36 enrolled 16 charts
Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia
Phase 3 Terminated
43 enrolled
Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
Phase 2 Terminated
82 enrolled
Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer
Phase NA Terminated
8 enrolled